Macrophage-Targeted TLR Compounds for Reversing Fibrosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for fibrotic diseases and cancers lack specificity and effectiveness, often relying on highly potent drugs that are poorly selective, leading to systemic toxicity and inability to halt disease progression or reverse fibrosis.
Innovation Solution
Development of compounds comprising a targeting moiety, such as a folate receptor binding ligand, linked to a toll-like receptor (TLR) agonist via a linker, to reprogram M2-type macrophages to M1-type macrophages, thereby disrupting profibrotic and pro-growth factor cycles with high specificity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If highly potent drugs are used to treat fibrotic diseases and cancers, then therapeutic effectiveness is improved, but systemic toxicity increases due to poor selectivity
Solution Approach 1:
The compound is segmented into distinct functional modules: a targeting moiety (folate receptor binding ligand) that provides selectivity for activated macrophages, a linker that connects the targeting moiety to the immune modulator, and an immune modulator (TLR agonist) that provides therapeutic effect. This segmentation allows each component to perform its specific function independently, achieving both effectiveness and selectivity.
Solution Approach 2:
The targeting moiety acts as an intermediary that mediates between the immune modulator and the activated macrophages. It binds specifically to folate receptors on activated macrophages, delivering the immune modulator precisely to the target cells while preventing systemic distribution and toxicity. This intermediary function resolves the contradiction by enabling potent therapy without systemic harm.
2Reliability
If conventional chemotherapeutic agents are used at high doses to treat cancer, then tumor inhibition is improved, but toxicity to normal cells increases
Solution Approach 1:
The compound exhibits local quality by concentrating therapeutic activity specifically at the site of activated macrophages through the targeting moiety's selective binding to folate receptors on these cells. The immune modulator is delivered locally to reprogram M2-type macrophages to M1-type macrophages at the disease site, achieving potent tumor inhibition and fibrosis disruption without affecting normal cells systemically.
3Duration of action of stationary object
If non-specific drugs are used to treat fibrotic diseases, then disease progression may be retarded, but the ability to halt or reverse fibrosis is lost due to lack of selectivity
Solution Approach 1:
The invention extracts and targets the specific pathological mechanism driven by activated M2-type macrophages. By taking out the selective targeting of these cells through the folate receptor-binding ligand, the compound can halt and reverse fibrosis by reprogramming the specific cell type responsible for profibrotic cytokine secretion, rather than merely retarding overall disease progression with non-specific drugs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively downregulate profibrotic markers and upregulate antifibrotic markers, reducing fibrosis and cancer progression by targeting activated macrophages, while minimizing systemic toxicity.
Implementation Method 1
a targeting moiety, such as a folate receptor binding ligand
Implementation Method 2
linked to a toll-like receptor (TLR) agonist via a linker, to reprogram M2-type macrophages to M1-type macrophages
Data Source
AI summary
Compounds, pharmaceutical compositions and methods are provided for reprogramming M2-like macrophages to M1-like macrophages, which reverses the antifibrotic to profibrotic shift observed during the course of fibrotic diseases and certain cancers. The compounds comprise an immune modulator that targets a pattern recognition receptor of a cell and are specific to the cells of interest through the incorporation of a targeting moiety (e.g., folate or a functional fragment or analog thereof). Releasable and/or non-releasable linkers can be included and engineered to facilitate the optimal delivery of the immune modulator. The compounds and compositions can be employed in one or more methods of treatment for fibrotic diseases and/or cancers.